Company / Depreciation & Amortization
Matinas BioPharma Holdings, Inc. Depreciation & Amortization History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$365.0K
FY2024
5-year range
$231.1K / $365.0K
FY2020-FY2024
Trend
+8.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $244,000 to $365,000 over the past 2 years.
Based on SEC 10-K filings.
$365,000 in FY2024 with a 5-year CAGR of +10.8%.
Increased from $244,000 to $365,000 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +14.4%
- 5-Year CAGR
- +10.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +10.8%, indicating consistent growth.
- In FY2024, depreciation & amortization increased 8.3% year-over-year.
- Lowest depreciation & amortization in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $365.0K | +8.3% |
| FY2023 | $337.0K | +38.1% |
| FY2022 | $244.0K | +0.0% |
| FY2021 | $244.0K | +5.6% |
| FY2020 | $231.1K | +5.8% |
| FY2019 | $218.3K | +117.0% |
| FY2018 | $100.6K | +131.3% |
| FY2017 | $43.5K | -17.4% |
| FY2016 | $52.6K | +21.0% |
| FY2015 | $43.5K | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026